Anti-Tumour TreatmentUntying the gordion knot of targeting MET in cancer
Section snippets
Overview of MET axis
MET proto-oncogene on chromosome 7q31 encodes a receptor tyrosine kinase which coupled with its ligand, HGF (hepatocyte growth factor), activates several downstream pathways that promote tumor growth, survival, and angiogenesis (Fig. 1) [1]. Additionally, this signaling can rework cytoskeletal framework and adhesions, triggering cellular morphogenesis and motility necessary for tumor invasion, migration and metastasis [1]. Through extensive functional cross-talk, MET can also mediate resistance
Road travelled thus far
Failure of randomized phase 2 study of MET antibody, Onartuzumab (Genentech) combined with erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) was the first of these unsuccessful attempts [5]. The premise was that MET inhibition will overcome acquired resistance to targeting epidermal growth factor receptor (EGFR), but no improvement in progression-free survival (PFS) or overall survival (OS) was seen. Notably, the study did not require any biomarker selection. However, both
Lessons learned
One clear miscalculation in most of these studies was an unselected population. The other common theme was use of protein overexpression by IHC as a biomarker either for selection strategy or for post-hoc assessment of efficacy. The attraction of IHC is understandable. It is relatively inexpensive, readily available, and most importantly a high prevalence biomarker in most cancers. There are however two major caveats with this strategy. Firstly, given that MET expression is seen in normal
Search for the optimal biomarker
To date, MET trials have used protein expression by IHC as a biomarker for selection. The success of IHC as a feasible and effective biomarker is evident from the experience with hormone receptor positive breast cancer. However, in other cases, presence of protein expression, such as HER2 in gastric cancer, does not sufficiently predict efficacy of anti-HER2 therapy [28]. Early studies have demonstrated the limited ability of MET protein expression in predicting efficacy of anti-MET therapies.
Alchemy of MET inhibitors
The ideal MET inhibitor should be a high potency antagonist; both of ligand-dependent and ligand-independent MET signaling without any agonist activity. There have been some shortcomings in earlier generation of MET inhibitors. Firstly, although in theory, HGF antibodies, such as Rilotumumab, can inhibit MET by neutralizing ligand–receptor interaction, they may not be effective in cases of where activation of the axis occurs in a ligand-independent fashion, such as MET amplifications or
Challenges of patient selection
Selecting the right drug and right biomarker is almost as crucial as selecting the right clinical setting. Therefore the next tier of questioning that ensues is whether MET inhibition, in and of itself, will be sufficient to improve clinical responses, whether innate/acquired mechanisms of resistance can blunt this effect and whether co-targeting these pathways will be more effective.
The success of targeting MET relies heavily on the dependence of tumors on the MET pathway for survival,
Conclusions
In spite of extensive pre-clinical data and abundance of therapeutic agents, developing a successful clinical trial targeting MET has eluded us. There are three core reasons behind this subpar progress. Firstly, although dysregulation of MET signaling is common in diverse tumor types the relative importance of these alterations (overexpression vs. mutations vs. amplifications) in tumor biology is largely unknown. Defining this would be a significant factor in selecting appropriate biomarker in
Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Conflicts of interest
No conflicts of interest.
Financial support
No financial disclosures.
References (74)
- et al.
Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer
Ann Oncol: Official J Eur Soc Med Oncol/ESMO
(2015) - et al.
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
Lancet Oncol
(2013) - et al.
Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study
Lancet Oncol
(2014) - et al.
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Lancet
(2010) - et al.
MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naive cohort
J Thoracic Oncol: Official Publ Int Assoc Study Lung Cancer
(2008) - et al.
Recurrent gene amplifications in human type I endometrial adenocarcinoma detected by fluorescence in situ hybridization
Cancer Genet Cytogenet
(2008) - et al.
Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment
Cancer Lett
(2016) - et al.
Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer
J Thoracic Oncol: Official Publ Int Assoc Study Lung Cancer
(2012) - et al.
High-MET status in non-small cell lung tumors correlates with receptor phosphorylation but not with the serum level of soluble form
Lung Cancer
(2016) - et al.
Identification of a novel type of alternative splicing of a tyrosine kinase receptor. Juxtamembrane deletion of the c-met protein kinase C serine phosphorylation regulatory site
J Biol Chem
(1994)
Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein
Mol Cell
Enhanced expression and phosphorylation of the MET oncoprotein by glioma-specific PTPRZ1-MET fusions
FEBS Lett
Met, metastasis, motility and more
Nat Rev Mol Cell Biol
Role of HGF/MET axis in resistance of lung cancer to contemporary management
Translational lung cancer Res
Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic
Clin Cancer Res: Official J Am Assoc Cancer Res
CMET and phospho-cMET protein levels in breast cancers and survival outcomes
Clin Cancer Res: Official J Am Assoc Cancer Res
Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer
J Clin Oncol: Official J Am Soc Clin Oncol
Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib+/-onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit
Clin Cancer Res: Official J Am Assoc Cancer Res
Results from the phase III randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV Non-Small-Cell Lung Cancer: METLung
J Clin Oncol: Official J Am Soc Clin Oncol
A randomized Phase II study of FOLFOX with or without the MET inhibitor onartuzumab in advanced adenocarcinoma of the stomach and gastroesophageal junction
Oncologist
A Phase II randomized trial (GO27827) of first-line FOLFOX plus Bevacizumab with or without the MET inhibitor onartuzumab in patients with metastatic colorectal cancer
Oncologist
Randomized, double-blind, placebo-controlled, multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in patients with recurrent glioblastoma: efficacy, safety, and hepatocyte growth factor and O6-methylguanine-DNA methyltransferase biomarker analyses
J Clin Oncol: Official J Am Soc Clin Oncol
Phase III multinational, randomized, double-blind, placebo-controlled study of Tivantinib (ARQ 197) plus Erlotinib versus Erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer
J Clin Oncol: Official J Am Soc Clin Oncol
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study
Lancet Oncol
A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy
Int J Cancer
A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer
Invest New Drugs
Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer
Invest New Drugs
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma
J Clin Oncol: Official J Am Soc Clin Oncol
Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
Invest New Drugs
Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer
PLoS ONE
Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer
Breast Cancer Res Treat
Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma
J Clin Oncol: Official J Am Soc Clin Oncol
Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition
Cancer Res
MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome
Br J Cancer
Cited by (18)
MET overexpression correlated with prognosis of EGFR-mutant treatment‑naïve advanced lung adenocarcinoma: a real‑world retrospective study
2024, Clinical and Translational OncologyWingless/It/β-catenin signaling in liver metastasis from colorectal cancer: A focus on biological mechanisms and therapeutic opportunities
2023, World Journal of GastroenterologyA novel peptide targeting c-Met for hepatocellular carcinoma diagnosis
2021, Journal of Materials Chemistry B